Kodiak Sciences to Present at Upcoming Investor Conferences

Core Insights - Kodiak Sciences Inc. is a precommercial biotechnology company focused on developing transformative therapeutics for retinal diseases [2][4] - The company is advancing three late-stage clinical programs targeting the $15 billion anti-VEGF market [2] - Recent data from the APEX study indicates that 90% of patients achieved absence of intraretinal and subretinal fluid through week 20 in macular edema secondary to inflammation [4][5] Company Overview - Kodiak Sciences is committed to researching, developing, and commercializing next-generation retinal medicines to prevent and treat leading causes of blindness globally [2] - The company's ABC Platform utilizes molecular engineering to integrate protein-based and chemistry-based therapies [2] Upcoming Events - CEO Victor Perlroth will present at the Jefferies Global Healthcare Conference on November 17, 2025, and at the Evercore Healthcare Conference on December 3, 2025 [5]